Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Debt: 2020-2025

Historic Non-Current Debt for ImmunityBio (IBRX) over the last 5 years, with Sep 2025 value amounting to $316.1 million.

  • ImmunityBio's Non-Current Debt rose 15.53% to $316.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.1 million, marking a year-over-year increase of 15.53%. This contributed to the annual value of $284.4 million for FY2024, which is 83.00% up from last year.
  • ImmunityBio's Non-Current Debt amounted to $316.1 million in Q3 2025, which was up 2.96% from $307.0 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Non-Current Debt peaked at $480.0 million during Q3 2023, and registered a low of $155.4 million during Q4 2023.
  • Over the past 3 years, ImmunityBio's median Non-Current Debt value was $279.0 million (recorded in 2024), while the average stood at $278.5 million.
  • Over the last 5 years, ImmunityBio's Non-Current Debt had its largest YoY gain of 83.00% in 2024, and its largest YoY loss of 42.99% in 2024.
  • Over the past 5 years, ImmunityBio's Non-Current Debt (Quarterly) stood at $306.3 million in 2021, then rose by 23.10% to $373.3 million in 2022, then grew by 28.59% to $155.4 million in 2023, then surged by 83.00% to $284.4 million in 2024, then increased by 15.53% to $316.1 million in 2025.
  • Its last three reported values are $316.1 million in Q3 2025, $307.0 million for Q2 2025, and $296.3 million during Q1 2025.